Study on AUNIP as a Novel Tumor Marker for Cervical Cancer
1 other identifier
observational
300
0 countries
N/A
Brief Summary
To detect the expression of AUNIP in cervical cancer serum, and to clarify its diagnostic and prognostic value.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2024
Longer than P75 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 31, 2023
CompletedFirst Posted
Study publicly available on registry
November 7, 2023
CompletedStudy Start
First participant enrolled
January 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
January 1, 2029
November 9, 2023
November 1, 2023
3.8 years
October 31, 2023
November 6, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
AUNIP expression in serum
Serum AUNIP expression is detected by ELISA kit. The results will be recorded seperately.
through study completion, an average of 3 year
Study Arms (2)
study group
Women aged 20-60; There is a definite pathological diagnosis of cervical cancer
Healthy control group
Women aged 20-60; No tumors in the uterus or other parts of the body; No inflammatory disease; Blood routine and blood biochemical tests are normal.
Interventions
The experiment is carried out according to the ELISA kit instructions, and the absorbance optic density (OD) value of the enzyme labeler at 450 nm is read. The protein concentration of AUNIP in the serum sample is calculated according to the standard curve.
Eligibility Criteria
In this study, 150 patients with cervical cancer in the First Affiliated Hospital of Shandong First Medical University (Shandong Qianfoshan Hospital) are selected as the study group. 150 healthy women are taken as control group during the same period.
You may qualify if:
- Women aged 20-60
- There is a definite pathological diagnosis of cervical cancer
- Healthy control group:
- Women aged 20-60
- No tumors in the uterus or other parts of the body
- No inflammatory disease
- Blood routine and blood biochemical tests are normal
You may not qualify if:
- There are other lesions in the uterus and uterine adnexa
- Pregnant, lactating or menarche women
- Women who are undergoing human papillomavirus (HPV) vaccination
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Lin Yuanlead
Related Publications (2)
Yang Z, Liang X, Fu Y, Liu Y, Zheng L, Liu F, Li T, Yin X, Qiao X, Xu X. Identification of AUNIP as a candidate diagnostic and prognostic biomarker for oral squamous cell carcinoma. EBioMedicine. 2019 Sep;47:44-57. doi: 10.1016/j.ebiom.2019.08.013. Epub 2019 Aug 10.
PMID: 31409573BACKGROUNDMa C, Kang W, Yu L, Yang Z, Ding T. AUNIP Expression Is Correlated With Immune Infiltration and Is a Candidate Diagnostic and Prognostic Biomarker for Hepatocellular Carcinoma and Lung Adenocarcinoma. Front Oncol. 2020 Dec 9;10:590006. doi: 10.3389/fonc.2020.590006. eCollection 2020.
PMID: 33363020BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Lin Yuan, Ph.D.
Qianfoshan Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
October 31, 2023
First Posted
November 7, 2023
Study Start
January 1, 2024
Primary Completion (Estimated)
October 1, 2027
Study Completion (Estimated)
January 1, 2029
Last Updated
November 9, 2023
Record last verified: 2023-11